US006660831B2

(12) **United States Patent**
Fallon

(10) **Patent No.: US 6,660,831 B2**
(45) **Date of Patent: Dec. 9, 2003**

(54) **METHOD FOR DIAGNOSING AND TREATING DYSAUTONOMIA AND OTHER DYSAUTONOMIC CONDITIONS**

(76) Inventor: **Joan M. Fallon**, 1284 Central Ave., Suite 1B, Yonkers, NY (US) 10704

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/929,592**

(22) Filed: **Aug. 14, 2001**

(65) **Prior Publication Data**

US 2002/0037284 A1 Mar. 28, 2002

Related U.S. Application Data

(60) Provisional application No. 60/224,991, filed on Aug. 14, 2000.

(51) **Int. Cl.**[7] **A61K 38/00**; A61K 39/00

(52) **U.S. Cl.** **530/309**; 424/198.1; 514/12

(58) **Field of Search** 433/4; 514/12; 600/350; 424/198.1; 530/309

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,648,335 A		7/1997	Lewis et al.	514/12
5,958,875 A		9/1999	Longo et al.	514/11
6,020,310 A	*	2/2000	Beck et al.	514/12
6,020,314 A		2/2000	McMichael	514/21
6,197,746 B1	*	3/2001	Beck et al.	514/12

FOREIGN PATENT DOCUMENTS

EP	0 564 739 A3	10/1993
EP	0 564 739 A2	10/1993
WO	WO 95 22344 A1	8/1995
WO	WO 98 22499 A2	5/1998
WO	WO 99 64059 A3	12/1999
WO	WO 99 64059 A2	12/1999

OTHER PUBLICATIONS

New York University School of Medicine, Grant Recipient Awards, Mar. –May 2000, www.med.nyu.edu/ogars/awards/awards 2000/page2.html, Axelrod, Felicia, *Secretin Treatment for Gastrointestinal Dysmobility in Patients with Familial Dysautonomia*.

* cited by examiner

Primary Examiner—Jon P. Weber
Assistant Examiner—Patricia A Patten
(74) *Attorney, Agent, or Firm*—F. Chau & Associates, LLP; Frank V. DeRosa, Esq.

(57) **ABSTRACT**

Methods for aiding in the diagnosis of dysautonomic disorders and dysautonomic conditions and methods for treating individuals diagnosed as having a dysautonomic disorder or a dysautonomic condition. In one aspect, a diagnosis method comprising analyzing a stool sample of an individual for the presence of a biological marker wherein the quantity of the biological marker is an indication of whether the invidual has, or can develop, a dysuatonic disorder or dysautonomic condition, as well as a therapuetic method for treating a dysautonomic disorder or dysautonomic condition by administration of, e.g., secretin, neuropeptides, peptides and/or digestive enzymes.

5 Claims, 3 Drawing Sheets